How Merck turned its wonder drug into a blockbuster — and priced out cancer patients worldwide

ICIJ says Merck has built a 1,212-application patent wall around Keytruda, with 211 granted patents potentially extending protection through at least 2042, 14 years beyond the original 2028 patent expiry. The investigation argues Merck’s pricing, lobbying and dosing strategies have kept Keytruda expensive globally, despite $163 billion in sales since 2014 and nearly $75 billion in dividends plus $43 billion in buybacks. The story also highlights acute affordability pressure across the U.S. and emerging markets, which could increase regulatory and political scrutiny on Merck and the broader pharma sector.

Analysis

MRK is facing a classic “good drug, bad economics” setup: Keytruda remains the franchise anchor, but the market is starting to discount the durability of its cash flows rather than the growth rate. The real second-order risk is not a near-term U.S. price cut — it is margin compression from a broader global payor backlash, where governments and hospital systems use reference pricing, reimbursement delays, and tender pressure to force lower net realized prices before the patent wall arrives. That pressure is most acute in ex-U.S. markets, where affordability optics are already politically toxic and can spread faster than legal patent challenges.

The patent overhang matters because it converts what would normally be a clean LOE event into a multi-year litigation and product-transition grind. If Merck succeeds with the SC formulation and dosing optimization, it could partially offset the 2028 cliff, but the market should view this as defense, not offense: a product hop can preserve share only if payors accept it as clinically meaningful, and that becomes harder when clinicians publicly endorse lower-dose alternatives. In other words, the more Merck leans on patent extensions and formulation switches, the more it invites antitrust, pricing, and reimbursement scrutiny.

The most important underappreciated issue is that the article attacks the sustainability of the entire immuno-oncology pricing model, not just Keytruda. If lower-dose/weight-based regimens gain formal adoption, the unit-volume story flips from growth to efficiency, creating a ceiling on revenue even if patient counts keep rising. That argues for a lower terminal multiple on MRK than peers with more diversified pipelines, because the Street is likely still overestimating how much of Keytruda’s current revenue can be “recycled” through new indications and dosing changes.

BAC and MCD are effectively incidental here. The broader policy signal is that Washington’s healthcare price rhetoric is moving from optics to targeted pressure, which can spill into managed-care, specialty pharmacy, and provider reimbursement names next if this campaign broadens beyond one flagship drug.

Key Decisions for Investors

• Short MRK on a 3-6 month horizon into strength; target a retracement toward a lower multiple as Keytruda exclusivity risk and pricing pressure get repriced. Best risk/reward is via put spreads to define downside while avoiding dividend carry.
• Pair trade: long diversified large-cap pharma with stronger post-2030 pipeline visibility vs short MRK. The trade benefits if investors rotate from single-asset monopoly durability to broader pipeline quality.
• Buy medium-dated MRK downside hedges ahead of patent/litigation milestones over the next 12-24 months; catalyst risk is asymmetric because any adverse payer, court, or dosing headline can compress the stock quickly.
• Watch for a temporary bounce on any U.S. pricing-exemption narrative; use that rally to add to shorts rather than chase weakness, since the more durable pressure is ex-U.S. reimbursement and patent-cliff related.
• Do not trade BAC or MCD on this story; the only relevant cross-asset read-through is that healthcare policy pressure is becoming more credible, which could later matter for managed care and healthcare distributors more than for consumer or bank names.